Favorable Immune Reconstitution Profile After Allogeneic Hematopoietic Stem Cell Transplantation With Post-Transplant Cyclophosphamide

Background: The administration of post-transplant high-dose cyclophosphamide (PTCy) has been shown to be an effective strategy for GvHD prophylaxis following allogeneic peripheral blood stem cell transplantation(PBSCT) from alternative donors. PTCy is toxic to allogeneic activated proliferating T lymphocytes, such as effector T cells. Conversely, it may not materially affect memory T cells.